Department of Urology, Osaka University Graduate School of Medicine, Japan.
BJU Int. 2011 Jun;107(12):1918-22. doi: 10.1111/j.1464-410X.2010.09804.x. Epub 2010 Nov 2.
• To evaluate tumour-associated macrophage (TAM) infiltration in prostate biopsy specimens as a possible prognostic factor for prostate cancer (PCa) after hormonal therapy.
• Immunostaining of TAMs in prostate biopsy specimens was performed using a monoclonal antibody CD68 for 71 patients having PCa treated with hormonal therapy. • Six microscopic (×400) fields around the cancer foci were selected for TAM counting.
• The median value of serum prostate-specific antigen (PSA) was 50.1 ng/mL, and the median TAM count was 22. • Recurrence-free survival was significantly better in patients with fewer TAMs (<22) than in those with higher numbers of TAMs (≥22) (P < 0.001). • TAM count was higher in those with higher serum PSA (PSA), higher Gleason score, clinical T stage or those with PSA failure. Cox multivariate analysis showed that TAM count is one of the prognostic factors for PCa treated by hormonal therapy (P < 0.0001).
• TAM infiltration in prostate needle biopsy specimens is a useful predictive factor for PSA failure or progression of PCa after hormonal therapy.
评估前列腺癌（PCa）患者激素治疗后肿瘤相关巨噬细胞（TAM）浸润作为一种可能的预后因素。
对 71 例接受激素治疗的 PCa 患者的前列腺活检标本进行 TAM 的免疫染色，使用单克隆抗体 CD68。选择 6 个围绕肿瘤焦点的显微镜（×400）视野进行 TAM 计数。
血清前列腺特异性抗原（PSA）中位数为 50.1ng/ml，TAM 计数中位数为 22。TAM 计数较低（<22）的患者无复发生存率明显优于 TAM 计数较高（≥22）的患者（P<0.001）。PSA、Gleason 评分较高、临床 T 分期较高或 PSA 失败的患者 TAM 计数较高。Cox 多因素分析显示，TAM 计数是激素治疗后 PCa 的预后因素之一（P<0.0001）。
前列腺活检标本中 TAM 浸润是激素治疗后 PSA 失败或 PCa 进展的一个有用的预测因子。
